291 related articles for article (PubMed ID: 27893470)
1. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
[TBL] [Abstract][Full Text] [Related]
2. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
3. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
Chin AL; Bentley JP; Pollom EL
Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
[TBL] [Abstract][Full Text] [Related]
8. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
9. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
[TBL] [Abstract][Full Text] [Related]
10. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
11. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
13. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
14. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Sedjo RL; Devine S
Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
[TBL] [Abstract][Full Text] [Related]
15. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
[TBL] [Abstract][Full Text] [Related]
16. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
[TBL] [Abstract][Full Text] [Related]
17. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
18. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
Hershman DL; Tsui J; Meyer J; Glied S; Hillyer GC; Wright JD; Neugut AI
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25349080
[TBL] [Abstract][Full Text] [Related]
19. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
Després F; Forget A; Kettani FZ; Blais L
J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
[TBL] [Abstract][Full Text] [Related]
20. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
